No Data
The subsidiary of BAIYUNSHAN PH (00874.HK), YUPINGFENG, has obtained approval for clinical trials for its tea bags.
On March 25, GELONGHUI reported that BAIYUNSHAN PH (00874.HK) announced that recently, its subsidiary Guangzhou BAIYUNSHAN CHEN LIJI Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "CHEN LIJI Pharmaceutical Factory") received the "Approval Notification for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration. According to relevant regulations, after review, the clinical trial application for YUPINGFENG tea bags submitted on December 30, 2024, meets the relevant requirements for pharmaceutical registration. Based on further improvements to the clinical trial plan, the approval is granted for this product to conduct trials for subclinical hypothyroidism and clinical hypothyroidism in patients with Hashimoto's thyroiditis who have normal thyroid function after LT4 treatment, along with spleen and lung qi deficiency syndrome.
BAIYUNSHAN PH (600332.SH): The subsidiary has received the approval notification for the clinical trial of a drug.
On March 25, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary Guangzhou BAIYUNSHAN Chenlij Medicine Factory Co., Ltd. (referred to as "Chenlij Medicine Factory") received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The functions and indications of Yupingfeng tea bags are to tonify qi, consolidate the exterior, and stop sweating. It is used for deficiencies of the exterior leading to spontaneous sweating, aversion to wind, pale complexion, or symptoms of fatigue in people with spleen and lung qi deficiency prone to wind evil. This product is an already marketed Traditional Chinese Medicine compound preparation, and this time aims to add functions and indications for the improvement of symptoms in subclinical hypothyroidism and clinical hypothyroidism in Hashimoto's thyroiditis patients treated with LT4 to achieve normal thyroid function.
[Brokerage Focus] CITIC SEC: The integration of the Traditional Chinese Medicine Industry is accelerating, and the leading players are expected to strengthen their position.
Jinwu Financial News | CITIC SEC states that the price of Traditional Chinese Medicine materials has entered a downward channel, and improvements in industrial costs are worth anticipating. Starting in January 2025, Traditional Chinese Medicine companies will successively complete inventory clearance through channels, and numerous e-commerce activities will occur during the Spring Festival, with strong purchasing power among Consumers. The e-commerce platforms' sales of Pharmaceutical products generally achieve high year-on-year growth rates. Benefiting from policy support and the accelerated aging of the population, the bank expects that overall demand for Traditional Chinese Medicine will continue to improve in the future, with industry consolidation accelerating, and leading companies are likely to become stronger.
Hong Kong stock Concept tracking | Promoting the value assessment and allocation of Traditional Chinese Medicine Pharmaceuticals, Institutions are Bullish on the recovery of Traditional Chinese Medicine revenue (with attached Concept stocks)
The General Office of the State Council issued the "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry."
Research Reports on Digging for Gold丨CICC: Maintain BAIYUNSHAN PH "Outperform Industry" rating, Target Price 34 yuan.
China International Capital Corporation's Research Reports indicate that BAIYUNSHAN PH (600332.SH) will have a revenue of 74.993 billion yuan in 2024, down 0.69% year-on-year; the Net income attributable to the parent company is 2.835 billion yuan, down 30.09% year-on-year; profits are below expectations, primarily due to the impairment provision for long-term Private Equity investments in Yixintang Pharmaceutical amounting to 0.386 billion yuan. During the period, the revenue of the Daan Pharmaceutical Sector declined, but some potential Traditional Chinese Medicine products maintained a good development trend. The sales revenue of products such as Yangyin Qingfei ointment, Yangyin Qingfei compound, Ammonium Guanfacine and Huangmin capsules, Cefaclor series (including raw materials), and Honey-fried Chuanbei Loquat Ointment achieved rapid year-on-year growth.
Baiyunshan Pharmaceutical Gets Nod to Outsource Ginger Granule Production
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
